Ethyl 5-hydroxy-7-chromancarboxylate | 151697-29-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: Ethyl 5-hydroxy-7-chromancarboxylate
• 英文别名: ethyl 5-hydroxy-3,4-dihydro-2H-chromene-7-carboxylate
• CAS: 151697-29-9
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: AEZRGGPTDRQHQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Ethyl 5-hydroxy-7-chromancarboxylate 在 lithium aluminium tetrahydride 、 正丁基锂 、 sodium hydride 、 potassium carbonate 、 一水合肼 作用下， 以 四氢呋喃 、 正己烷 、 二乙二醇 、 苯 为溶剂， 反应 9.0h， 生成 5-Methoxy-8-methyl-7-chromanmethanol
  参考文献：
  名称：

  Relevance of Conformational Constraints to the Regioselective Lithiation of Aromatic Diethers. Application to the Convenient Construction of the DEF Tricyclic Subunit of the Austalides

  摘要：

  The lithiation of 29 and 30 is shown to occur at all three sites with a dissimilar kinetic preference. For the dihydrofuran, reaction at the proton labeled H-beta, operates predominantly; in the dihydropyran example, H-alpha is the favored site of deprotonation. These protons represent those that are the most deshielded in the respective H-1 NMR spectra. The same is true for 9 and 19, both of which undergo metalation adjacent to the ring oxygen. No crossover in regioselectivity is observed, presumably because the methoxy substituent is sterically precluded from rotating freely. Mixed complexes (dimers, etc.) or mixed aggregates in low equilibrium concentration are key to understanding the acidification phenomenon of ortho hydrogens. As a consequence of the dominance of regiocontrol by the ring oxygen in 9, a convenient means has been developed for elaboration of the tricyclic eastern sector of the austalide mycotoxins.

  DOI：

  10.1021/jo00087a018
• 作为产物：
  描述：

  1-Ethyl hydrogen <<(E)-2,3-dihydro-2H-pyran-6-yl>methylene>succinate 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 以77%的产率得到Ethyl 5-hydroxy-7-chromancarboxylate
  参考文献：
  名称：

  烷氧基和环状醚氧具有不同的引导邻位锂化的能力

  摘要：

  的金属化图4a和图4b与Ñ动力学控制条件下正丁基锂（C 6 H ^ 6，20℃或Et 2 O，TMEDA（2当量），20℃）导致优选的脱质子化α到杂环。

  DOI：

  10.1016/s0040-4039(00)73670-7

文献信息

• Alkoxy and cyclic ether oxygens exhibit disparate capabilities for directing ortho lithiation
  作者：Leo A. Paquette、Matthias M. Schulze

  DOI：10.1016/s0040-4039(00)73670-7

  日期：1993.5

  Metalation of 4a and 4b with n-butyllithium under kinetically controlled conditions (C6H6, 20 °C or Et2O, TMEDA (2 equiv), 20 °C) leads to preferred deprotonation α to the heterocyclic ring.

  的金属化图4a和图4b与Ñ动力学控制条件下正丁基锂（C 6 H ^ 6，20℃或Et 2 O，TMEDA（2当量），20℃）导致优选的脱质子化α到杂环。
• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• Pequette, Leo A.; Schulze, Matthias M., Heterocycles, 1993, vol. 35, # 2, p. 585 - 589
  作者：Pequette, Leo A.、Schulze, Matthias M.

  DOI：——

  日期：——
• 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS
  申请人：Novartis AG

  公开号：EP1968940A1

  公开（公告）日：2008-09-17